Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00177-5/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=280173067&_hsenc=p2ANqtz-9OZ4dLs-rJNwq-8YfU3xkJU2CfZSdEFhsoW2Tm9vc_ew_HSpsj6vosd2FiU9S7kHiVw2kECGZWbbMftN4-03VANcbaGw&utm_content=280145645&utm_source=hs_email